The established link between impairment of these ER pathways and diseases such as breast and endometrial cancers, osteoporosis, metabolic and cardiovascular diseases (55, 109) explains the number of published in silico studies with a therapeutic scope (8 up to the 23 ER-related reviewed studies). Here, ESR1 is linked to osteoporosis.